GV and Nextech are among the participants in a series A round that is funding the launch of EQRx, which is developing cheaper copies of existing drugs.

US-based biosimilar medicine developer EQRx launched yesterday with $200m secured in a series A round featuring healthcare software provider Nextech and GV, a corporate venturing subsidiary of internet technology conglomerate Alphabet. The corporates were joined by healthcare investment firm Casdin Capital and venture capital firms Arch Venture Partners, Andreessen Horowitz, Section 32 and Arboretum Ventures.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.